Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Early Pfizer COVID-19 vaccine doses may have had potency problems

By Brian Buntz | March 24, 2021

bivalent COVID-19 vaccine

[Image courtesy of Wikimedia Commons]

Some of the first commercially available doses of Pfizer-BioNTech COVID-19 vaccine had lower levels of intact mRNA than anticipated, according to leaked documents reviewed by BMJ.

The documents in question relate to a December breach of the European Medicines Agency (EMA), which was one of the many victims of pharma-related cyber breaches in 2020.

The cybercriminals behind the attacks sent 40 MB of data to several journalists while also publishing them on the dark web.

The EMA has launched a criminal investigation related to the breach. The agency claimed in January that the leaked documents were modified. “A closer investigation of the published material has revealed that not all of the documents were published in their integral, original form and may have been taken out of context,” reads part of a statement.

Keanna Ghazvini, a Pfizer spokesperson acknowledged that some documents related to to the EMA’s rolling review of the Pfizer/BNT vaccine clinical program have been found online. “Discussions with the regulatory authorities about the vaccine’s quality aspects, including specifications, represent a normal component of the regulatory review process,” the spokesperson said. “All the topics that emerged during the procedure have been discussed transparently with the Agency, in accordance to the normal practices, and all questions have been duly addressed during the review process,” she added.

BMJ editors have reviewed the documents, which indicate that EMA officials were concerned about the low amounts of intact mRNA in early commercial batches of vaccines. According to one email, the impact of the loss is mRNA integrity has “yet to be defined,” according to one email.

An email from November 23 detailed concerns from a senior EMA official who worried that the early vaccine doses did not meet specifications, according to BMJ. The percent of intact mRNA in early doses was reportedly 55% to 78%.

EMA reportedly filed two “major objections” with Pfizer upon discovering the issues.

However, a later EMA email reported that the amount of intact RNA had risen to be in the range of 70 to 75%.

The organization authorized the vaccine on December 21. In February, it deemed the quality of the product to be “sufficiently consistent and acceptable.”

“The positive opinion granted by EMA and the subsequent conditional Marketing Authorization, issued on December 21, 2020, by the EC, are results of this process, meaning that all the questions raised during the procedure were addressed satisfactorily and the efficacy, safety and quality of the vaccine could be demonstrated on the data submitted,” the Pfizer spokesperson added.

The topic of mRNA stability does not apply only to Pfizer and its partner BioNTech. Several other companies, such as Moderna and CureVac, are also using the mRNA vaccine platform.


Filed Under: Drug Discovery and Development, Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccines, Moderna, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE